Skip to main content

Table 2 Univariable Firth’s logistic regression analysis for baseline characteristics and type of progression: OR (95%CI)

From: Mode of progression after radioembolization in patients with colorectal cancer liver metastases

 

PD

GIHM (n = 20)

GEHM (n = 37)

NIHM (n = 35)

NEHM (n = 57)

GM (n = 45)

NM (n = 63)

Age in years

1.02 (0.97; 1.07)

0.99 (0.02; 9.75)

1.01 (0.97; 1.06)

1.02 (0.98; 1.06)

1.00 (0.96; 1.05)

1.01 (0.97; 1.06)

1.01 (0.97; 1.05)

Chemotherapy*

0.88 (0.01; 88.46)

0.74 (0.26; 2.01)

0.87 (0.37; 2.05)

0.37 (0.14; 0.91)

0.63 (0.26; 1.51)

0.57 (0.24; 1.33)

0.48 (0.19; 1.19)

Type of microspheres**, Glass

1.11 (0.32; 4.53)

0.71 (0.18; 2.41)

2.53 (0.87; 7.56)

1.71 (0.59; 4.99)

1.5 (0.50; 4.89)

1.79 (0.62; 5.35)

1.94 (0.59–7.65)

Type of microspheres, holmium

0.67 (0.22; 2.14)

0.57 (0.14; 1.88)

1.75 (0.63; 4.86)

0.85 (0.29; 2.38)

0.90 (0.33; 2.50)

1.19 (0.44; 3.22)

0.81 (0.29–2.31)

Extrahepatic metastases at baseline

7.8 (2.37; 35.53)

2.39 (0.89; 6.84)

NA

1.83 (0.79; 4.32)

3.06 (1.28; 7.72)

NA

2.86 (1.14; 7.66)

Primary tumor in situ

1.90 (0.30; 37.11)

0.76 (0.08; 3.96)

1.12 (0.24; 4.88)

3.86 (0.87; 22.5)

2.73 (0.54; 27.1)

1.32 (0.30; 6.21)

2.00 (0.39; 19.9)

WHO status***

0.87 (0.32; 2.46)

0.43 (0.10; 1.43)

0.91 (0.35; 2.33)

0.90 (0.33; 2.33)

0.50 (0.19; 1.31)

0.86 (0.34; 2.19)

0.81 (0.30; 2.27)

KRAS status§

3.38 (0.75; 23.95)

1.88 (0.56; 6.45)

2.75 (0.90; 8.78)

4.78 (1.52; 16.5)

3.92 (1.11; 17.2)

2.85 (0.92; 9.48)

2.67 (0.74; 11.86)

Time since diagnosis of metastases§§

1.06 (1.01; 1.11)

0.98 (0.94; 1.01)

1.01 (0.99; 1.04)

0.98 (0.95; 1.01)

1.02 (0.99; 1.05)

1.01 (0.98; 1.03)

1.02 (0.99; 1.07)

CEA level before treatment

1.00 (0.99–1.00)

1.00 (95%CI 0.99–1.00)

1.00 (95%CI 0.99–1.00)

1.00 (95%CI 0.99–1.00)

1.00 (0.99–1.00)

1.00 (0.99–1.01)

1.00 (0.99–1.01)

Primary tumor location

3.88 (1.00–25.75)

0.88 (0.26–2.63)

0.98 (0.35–2.63)

1.72 (0.65–4.59)

2.96 (0.98–11.11)

0.94 (0.36–2.49)

3.88 (1.00–25.76)

Tumor load†, 25–50%

1.63 (0.50–6.35)

0.56 (0.14–1.79)

1.17 (0.42–3.16)

0.58 (0.20–1.59)

0.94 (0.34–2.72)

1.04 (0.39–2.74)

1.11 (0.36–3.90), 0.7

Tumor load, > 50%

0.73 (0.20–3.10)

1.24 (0.30–4.49)

1.67 (0.47–5.76)

1.64 (0.48–5.76)

0.55 (0.16–1.95)

1.66 (0.49–6.12)

0.66 (0.18–2.77)

  1. This table shows the associations (odds ratio and 95%CI) between baseline characteristics and modes of progression as described by RECIST at 3 months post-treatment
  2. Abbreviations: GIHM growth of intrahepatic metastases, GEHM growth of extrahepatic metastases, NIHM new intrahepatic metastases, NEHM new extrahepatic metastases, GM growth of metastases (GEHM + GIHM), NM new metastases (NEHM + NIHM), NA not applicable, RE radioembolization, OR odds ratio, PD progressive disease, 95% CI 95% confidence interval
  3. *Previous treatment with 1st- versus 2nd-line chemotherapy
  4. **Yttrium-90 resin (reference) versus yttrium-90 glass and holmium-166
  5. ***WHO performance status 0 versus 1, 2
  6. §KRAS mutation versus KRAS wild type
  7. §§Right-sided primary tumors versus left-sided primary tumors
  8. †< 25% liver involvement versus 25–50% and > 50% liver involvement
Back to article page